The Future Of Breast Cancer Therapy: An Interview With Peter D. Beitsch, MD, FACS

As breast cancer management moves toward a more patient-centric, personalized approach, patients and their doctors are being offered more treatment choices than ever before. (See Also see "The Evolving World Of Breast Cancer Management" - Medtech Insight, 6 July, 2012..) This expansion in options encompasses not only traditional areas, such as post-surgery radiation therapy, but now also involves new surgical techniques designed to provide better cosmetic results for the growing number of patients who choose mastectomy over breast-sparing lumpectomy as their treatment of choice. To gain additional insight into these trends, Medtech Insight recently spoke with Peter D. Beitsch, MD, FACS, director of the Dallas Breast Center, chief physician of the Dallas Surgical Group, Medical City Dallas Hospital, and co-principal investigator for the ongoing American Society of Breast Surgeons (ASBS)-directed MammoSite Registry, which is tracking the long-term outcomes of lumpectomy patients treated with Hologic Inc.’s MammoSite breast brachytherapy device. According to Dr. Beitsch, women are increasingly choosing mastectomy over breast-sparing lumpectomy and that trend is being driven in part by recent surgical advances, most notably the growing availability of nipple-sparing mastectomy, which he calls a “revolutionary” new oncoplastic technique.

Medtech Insight: How have advances in reconstructive surgery impacted breast cancer management in recent years?

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Surgical Procedures

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By 

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Ochsner Surgeon In ‘The Big Easy’ Eases Patient’s Pain With Skill And Virtual Reality

 

A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

More from Surgery

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.